IDEXX Laboratories (NASDAQ: IDXX) revenue
IDEXX Laboratories reported revenue of $4,304m for fiscal 2025, 10.4% more than in fiscal 2024 ($3,898m). Since fiscal 2016 its revenue has grown by 142.4%, an average growth of 10.3% a year.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $4,304m | +10.4% | $1,360m | 31.6% |
| 2024 | $3,898m | +6.5% | $1,128m | 29.0% |
| 2023 | $3,661m | +8.7% | $1,097m | 30.0% |
| 2022 | $3,367m | +4.7% | $898.8m | 26.7% |
| 2021 | $3,215m | +18.8% | $932.0m | 29.0% |
| 2020 | $2,707m | +12.5% | $694.5m | 25.7% |
| 2019 | $2,407m | +8.8% | $552.8m | 23.0% |
| 2018 | $2,213m | +12.4% | $491.3m | 22.2% |
| 2017 | $1,969m | +10.9% | $413.0m | 21.0% |
| 2016 | $1,775m | — | $350.2m | 19.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Questions about the revenue of IDEXX Laboratories
- How much revenue did IDEXX Laboratories make in fiscal 2025?
- IDEXX Laboratories reported revenue of $4,304m for fiscal 2025, compared with $3,898m in fiscal 2024.
- How much has the revenue of IDEXX Laboratories grown?
- Between fiscal 2016 and fiscal 2025 it went from $1,775m to $4,304m: 142.4% more, an average growth of 10.3% a year.
- What was the best year for revenue at IDEXX Laboratories?
- Of its last 10 fiscal years, fiscal 2025, with $4,304m.
- Where do the figures for IDEXX Laboratories come from?
- From the annual report (Form 10-K) that IDEXX Laboratories files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that IDEXX Laboratories files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on IDEXX Laboratories: the IDEXX Laboratories page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.